IN2012DN02535A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02535A IN2012DN02535A IN2535DEN2012A IN2012DN02535A IN 2012DN02535 A IN2012DN02535 A IN 2012DN02535A IN 2535DEN2012 A IN2535DEN2012 A IN 2535DEN2012A IN 2012DN02535 A IN2012DN02535 A IN 2012DN02535A
- Authority
- IN
- India
- Prior art keywords
- specificity
- fab
- antigen
- interest
- disulfide bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2009/002310 WO2010035012A1 (fr) | 2008-09-26 | 2009-09-25 | Produits biologiques |
GBGB1005063.1A GB201005063D0 (en) | 2010-03-25 | 2010-03-25 | Biological products |
PCT/GB2010/001803 WO2011036460A1 (fr) | 2009-09-25 | 2010-09-24 | Anticorps multivalents stabilisés par un pont disulfure |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02535A true IN2012DN02535A (fr) | 2015-08-28 |
Family
ID=42228366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2535DEN2012 IN2012DN02535A (fr) | 2009-09-25 | 2010-09-24 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120316324A1 (fr) |
EP (1) | EP2480577B1 (fr) |
JP (2) | JP5931730B2 (fr) |
CN (2) | CN105315374A (fr) |
BR (1) | BR112012006492A2 (fr) |
CA (1) | CA2773286C (fr) |
EA (1) | EA201200526A1 (fr) |
ES (1) | ES2736649T3 (fr) |
GB (1) | GB201005063D0 (fr) |
IN (1) | IN2012DN02535A (fr) |
TR (1) | TR201910213T4 (fr) |
WO (1) | WO2011036460A1 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2535351A3 (fr) | 2007-09-26 | 2013-04-03 | UCB Pharma S.A. | Fusions d'anticorps à double spécificité |
DK2334705T3 (en) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | BIOLOGICAL PRODUCTS |
US20120283415A1 (en) * | 2009-09-10 | 2012-11-08 | Ucb Pharma S.A. | Multivalent Antibodies |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
EP2987806A3 (fr) | 2011-08-17 | 2016-07-13 | Glaxo Group Limited | Anticorps modifiés à domaine variable unique présentant une diminution de liaison pour des anticorps anti-médicament |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
EP2753927B1 (fr) * | 2011-09-06 | 2017-11-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Procédé d'analyse de complexes macromoléculaires biologiques et utilisation de celui-ci |
CA2856216C (fr) | 2011-11-11 | 2021-01-12 | Ucb Pharma S.A. | Anticorps se liant a l'albumine et leurs fragments de liaison |
UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
SG11201506053VA (en) * | 2013-02-05 | 2015-08-28 | Sanofi Sa | Immuno imaging agent for use with antibody-drug conjugate therapy |
KR20150113197A (ko) * | 2013-02-05 | 2015-10-07 | 사노피 | 항체-약물 컨쥬게이트 치료법에 사용하기 위한 면역 영상제 |
JP2016515093A (ja) | 2013-02-05 | 2016-05-26 | サノフイ | 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤 |
US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US10047163B2 (en) | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
RU2015140917A (ru) * | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
CN110845618A (zh) * | 2013-02-26 | 2020-02-28 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
BR112016004355A2 (pt) * | 2013-08-30 | 2017-10-17 | Aprilbio Co Ltd | constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo |
HUE058272T2 (hu) | 2013-11-06 | 2022-07-28 | Janssen Biotech Inc | Anti-CCL17 antitestek |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
CN114605549A (zh) | 2015-08-05 | 2022-06-10 | 詹森生物科技公司 | 抗cd154抗体及其使用方法 |
US20180355043A1 (en) | 2015-12-17 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies Specifically Binding HLA-DR and Their Uses |
WO2018014260A1 (fr) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation |
WO2018068201A1 (fr) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Anticorps à domaine unique et ses variants contre ctla-4 |
CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
WO2018224439A1 (fr) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Nouveaux anticorps anti-hsa |
JP7130678B2 (ja) * | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗hsa抗体 |
CN110831978A (zh) | 2017-06-30 | 2020-02-21 | 酵活有限公司 | 稳定的嵌合fab |
CN111699198B (zh) | 2017-12-28 | 2023-09-05 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
EP3740507A4 (fr) * | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | Anticorps à domaine unique et des variants de celui-ci dirigés contre pd-1 |
CN110551216B (zh) * | 2018-05-31 | 2022-11-18 | 信达生物制药(苏州)有限公司 | 多价抗ox40抗体及其用途 |
CN115667316A (zh) * | 2020-06-30 | 2023-01-31 | 和铂医药(上海)有限责任公司 | Fab-HCAb结构的结合蛋白 |
EP4174092A4 (fr) * | 2020-06-30 | 2024-03-20 | Harbour Biomed Shanghai Co Ltd | Protéine de liaison multi-spécifique d'un recruteur de cellules immunitaires, préparation et utilisation associées |
AU2021322238A1 (en) | 2020-08-05 | 2023-03-23 | Synthekine, Inc. | Compositions and methods related to IL27 receptor binding |
MX2023004436A (es) | 2020-10-15 | 2023-05-08 | UCB Biopharma SRL | Moleculas de union que multimerizan cd45. |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
EP1690935A3 (fr) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Génération d'anticorps xenogéniques |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (fr) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methodes de production de proteines dotees d'une fonction desiree |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
WO1992018619A1 (fr) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Banques de recepteurs heterodimeres utilisant des phagemides |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
US5747654A (en) * | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
CA2249195A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
DE19653722C2 (de) | 1996-12-10 | 2000-06-29 | Brose Fahrzeugteile | Beidseitig wirkende Verstellvorrichtung |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
DE69821338T2 (de) | 1997-02-21 | 2004-10-21 | Genentech Inc | Antikörperfragment-polymerkonjugate |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
JP2002536968A (ja) * | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Kdrに特異的な抗体およびその使用 |
ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
EP2386575A3 (fr) | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Anticorps à double spécificité et leurs procédés de fabrication et d'utilisation |
EP1377306A1 (fr) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Groupes de liaison d'albumine serique |
CA2490009A1 (fr) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Ligands propres a un cible et associes a une proteine serique et procede d'identification correspondant |
SI1517921T1 (sl) | 2002-06-28 | 2006-10-31 | Domantis Ltd | Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo |
CA2505326A1 (fr) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Procede d'administration de polypeptides therapeutiques et polypeptides associes |
ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
JP2007536898A (ja) | 2003-07-01 | 2007-12-20 | セルテック アール アンド ディ リミテッド | 修飾抗体Fabフラグメント |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
EP1784427A2 (fr) | 2004-06-01 | 2007-05-16 | Domantis Limited | Anticorps de fusion bispecifiqus avec une demi-vie augmentee |
MX2007014359A (es) | 2005-05-18 | 2008-02-06 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
BRPI0615026A8 (pt) | 2005-08-19 | 2018-03-06 | Abbott Lab | imunoglobulina de domínio variável duplo e seus usos |
CN101448853A (zh) * | 2006-03-17 | 2009-06-03 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
KR101516823B1 (ko) * | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
EP2535351A3 (fr) * | 2007-09-26 | 2013-04-03 | UCB Pharma S.A. | Fusions d'anticorps à double spécificité |
DK2334705T3 (en) * | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | BIOLOGICAL PRODUCTS |
-
2010
- 2010-03-25 GB GBGB1005063.1A patent/GB201005063D0/en not_active Ceased
- 2010-09-24 EP EP10761060.2A patent/EP2480577B1/fr active Active
- 2010-09-24 CA CA2773286A patent/CA2773286C/fr not_active Expired - Fee Related
- 2010-09-24 EA EA201200526A patent/EA201200526A1/ru unknown
- 2010-09-24 BR BR112012006492A patent/BR112012006492A2/pt not_active Application Discontinuation
- 2010-09-24 WO PCT/GB2010/001803 patent/WO2011036460A1/fr active Application Filing
- 2010-09-24 JP JP2012530333A patent/JP5931730B2/ja not_active Expired - Fee Related
- 2010-09-24 CN CN201510638852.8A patent/CN105315374A/zh active Pending
- 2010-09-24 ES ES10761060T patent/ES2736649T3/es active Active
- 2010-09-24 CN CN201080042387.7A patent/CN102549018B/zh not_active Expired - Fee Related
- 2010-09-24 TR TR2019/10213T patent/TR201910213T4/tr unknown
- 2010-09-24 US US13/498,017 patent/US20120316324A1/en not_active Abandoned
- 2010-09-24 IN IN2535DEN2012 patent/IN2012DN02535A/en unknown
-
2016
- 2016-02-29 JP JP2016037645A patent/JP2016106126A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2773286C (fr) | 2020-10-20 |
CN105315374A (zh) | 2016-02-10 |
JP2013505923A (ja) | 2013-02-21 |
BR112012006492A2 (pt) | 2016-11-22 |
JP2016106126A (ja) | 2016-06-16 |
WO2011036460A1 (fr) | 2011-03-31 |
ES2736649T3 (es) | 2020-01-03 |
EP2480577B1 (fr) | 2019-04-10 |
CA2773286A1 (fr) | 2011-03-31 |
CN102549018B (zh) | 2015-11-25 |
US20120316324A1 (en) | 2012-12-13 |
GB201005063D0 (en) | 2010-05-12 |
EA201200526A1 (ru) | 2012-11-30 |
EP2480577A1 (fr) | 2012-08-01 |
JP5931730B2 (ja) | 2016-06-08 |
TR201910213T4 (tr) | 2019-07-22 |
CN102549018A (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02535A (fr) | ||
CY1118713T1 (el) | Βιολογικα προϊοντα | |
EP2535351A3 (fr) | Fusions d'anticorps à double spécificité | |
EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
WO2008097817A3 (fr) | Complexes d'antigènes multivariables et d'un anticorps monoclonal humanisé cible | |
WO2016154047A3 (fr) | Protéines de liaison à l'antigène monoclonales à des produits oncogènes intracellulaires | |
CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
WO2013054331A8 (fr) | Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcinoembryonnaire (ceacam) | |
AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
AU2010234031A8 (en) | Trivalent, bispecific antibodies | |
RU2011148913A (ru) | Иммуноглобулин с двумя вариабельными доменами и его применение | |
NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof | |
WO2008098917A3 (fr) | Nouveaux anticorps | |
NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
WO2007067596A3 (fr) | Procedes et compositions servant a l'apport, sans aiguille, d'anticorps | |
IL212056A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
NZ586357A (en) | Antibodies to the pcrv antigen of pseudomonas aeruginosa | |
EP3300739A3 (fr) | Anticorps et molécules correspondantes se liant aux protéines 161p2f10b | |
MX2010001237A (es) | Nuevos anticuerpos. | |
MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
WO2011064257A3 (fr) | Réactifs polypeptidiques monospécifiques | |
WO2008140487A3 (fr) | Molecules ameliorees se liant a la proteine a staphylococcique, heteropolymeres les contenant et methodes d'utilisation associees | |
WO2006060719A3 (fr) | Utilisation de proteines de liaison a l'endosialine afin d'isoler des cellules positives pour l'endosialine | |
MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. |